Glenmark Pharmaceuticals on Friday announced that it had been granted final approval by the United States Food & Drug Administration (USFDA) for Fingolimod capsules, 0.5 mg, the generic version of Gilenya1 capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.
According to IQVIATM sales data for the 12 months ending April 2020, the Gilenya capsules, 0.5 mg market achieved annual sales of approximately $2.1 billion.
Shares of the company trade over 2 per cent higher at Rs 417.